Introduction:
China’s healthcare sector is facing increased oversight from stock exchanges, causing many companies to reconsider their initial public offering (IPO) ambitions. This change follows the recent anti-corruption drive, with authorities zeroing in on alleged malpractices within the pharmaceutical realm. This article delves into the factors leading to this scrutiny, the companies most affected, and the broader implications for China’s financial and healthcare sectors.
Background:
Late July marked the commencement of a year-long anti-corruption initiative by the Chinese government, focusing on purported widespread bribery incidents involving doctors during the sale of drugs and medical equipment. With healthcare shares already experiencing a downturn due to this campaign, the pharmaceutical arena is now under the microscope of Chinese regulators.
Pharmaceuticals and IPOs:
China has been making efforts to overhaul its IPO system, transitioning to a more market-centric model. Despite the shift, the influence of regulators over corporate fundraising endeavors is evident, especially in light of increased IPO scrutiny for pharmaceutical companies. This new level of examination underscores the regulators’ intent to ensure a transparent and corruption-free healthcare sector.
Notable Cases and their Implications:
Shanghai-based vaccine producer, Shanghai Rongsheng Biotech Co., recently shelved its IPO aspirations. This decision came after the company’s elevated sales expenses — equating to one-third of its revenue over the past three years — raised eyebrows among regulators. The Shanghai Stock Exchange, in response, inquired about potential undisclosed transfers of interests to customers, as per securities filings.
Another enterprise, Fujian Mindong Rejuenation Pharmaceutical Co., decided to pull its IPO application. This move was influenced by queries from the Shenzhen Stock Exchange, probing the justification behind its sales promotion strategies, encompassing academic seminars. Remarkably, this company’s sales expenses for the last three years were nearly 50% of its revenue.
In the context of the anti-corruption movement, such high sales expenses have become focal points for regulators. An anonymous Shanghai-based IPO banker commented on the heightened strictness concerning IPO vetting, stating that the examination of pharmaceutical companies’ IPO applications has become stringent.
The overall uncertainty and detailed questions about sales expenditures have led many drug manufacturers to hold off on their IPO endeavors.
Communication Breakdown?
Attempts to reach out to Rongsheng and Fujian Mindong for comments remained unanswered, both through emails and calls, as per the details from their prospectuses. In defense against the stock exchanges’ inquiries, both companies claimed that their sales operations are logical and they aren’t involved in any undisclosed transfers of interests.
Reuters’ attempts to elicit responses from the Shanghai and Shenzhen exchanges also went unanswered.
Trends and Figures:
Available data indicates a growing reluctance among healthcare corporations in China to go public. This year, at least 12 healthcare entities have put a stop to their IPO plans. In comparison to the same timeframe the previous year, only 14 healthcare-related stocks have been listed in the current year, a significant drop from the 27 listings.
Broader Crackdowns and Impacts on the Market:
China’s regulatory environment is known for its sweeping crackdowns across various sectors. Historically, areas like tutoring, fintech, and real estate have faced similar oversight, resulting in significant market value reductions. For pharmaceutical companies that are already publicly traded, their stock values have been negatively affected by the anti-corruption drive, likely affecting future sales.
Concluding Remarks:
The intensity of this anti-corruption wave is unparalleled. Evidence of this can be found in recent reports by healthcare information provider, Saibailan, indicating that at least 168 hospital directors are currently under investigation — a figure that’s doubled since 2022. Several medical conferences have been deferred, with the National Health Commission of China suspecting their use as bribery channels.
The profound impacts of this drive are evident, with many industry insiders voicing their concerns. One anonymous manager at a medical equipment production firm summarized the situation aptly: “This round of anti-graft is much stronger than before, and its impact is huge. Sales in many firms would be affected.”
As China continues its aggressive anti-corruption campaign, companies within the healthcare sector are on high alert. The impact on IPOs, share prices, and sales paints a cautionary tale for other industries as well.
Read More: